Medtronic gives it another go with atrial fibrillation device

Medtronic ($MDT) is looking to make its device the first to be FDA-approved for long-running atrial fibrillation, shaking off a 2011 setback and kick-starting enrollment in a new pivotal trial.

The Phased RF system uses radiofrequency energy to ablate tissues and treat instances of the dangerous heart rhythm disorder that last between 7 days and four years, the company said. Through the VICTORY AF trial, Medtronic will test the device in 350 long-lasting AF patients with the goal of convincing the FDA to make Phased RF a first-of-its-kind device--right now, the only approved AF-treating technologies are indicated for episodes lasting less than a week.

The latest trial is a second go-round for Medtronic after an FDA advisory panel ruled in 2011 that while Phased RF was plenty effective in preventing future strokes, the device's safety profile was questionable. With VICTORY AF, Medtronic's primary endpoint is a 30-day procedure-related stroke rate below 1.8%, and the company is confident it can succeed where its previous effort failed.

"In strong collaboration with the FDA, we designed the VICTORY AF trial to evaluate the safety of Phased RF ablation in patients who suffer with persistent or long-standing persistent AF," Medtronic AF chief Reggie Groves said in a statement. "We expect this trial will demonstrate its safety and benefit for this patient population."

Phased RF is made up of a generator and some multi-electrode catheters designed to counteract impulses in the left atrium that contribute to AF. The device is already approved overseas and has been used on more than 20,000 patients in 26 countries since 2009, according to Medtronic.

- read the statement

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

A COVID-19 antibody diagnostic developed through a joint venture between Mount Sinai Health System and RenalytixAI has been authorized by the FDA.

Researchers at Northwestern University have trained an AI algorithm to automatically detect the signs of COVID-19 on a basic X-ray of the lungs.

Hand-held ultrasound developer Butterfly Network is going public through a $1.5 billion acquisition deal backed by Glenview Capital.